Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.55 USD
+0.09 (6.16%)
Updated Apr 19, 2024 03:59 PM ET
After-Market: $1.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PACB 1.55 +0.09(6.16%)
Will PACB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down
Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Other News for PACB
PacBio price target lowered by $7 at Scotiabank, here's why
PacBio cut to Neutral at Goldman Sachs after guidance cut
Cathie Wood's ARK Investment buys 255.3K shares of PacBio today
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY)
PacBio price target lowered by $6.50 at Bernstein, here's why